The Investigational Cellular Therapy (ICT) program benefits from a wide variety of academic and industry collaborations.
These partnerships are critical to rapidly advance promising new tools and technologies, support our ongoing clinical manufacturing, and deliver better cell and gene therapies directly to our patients.
